Loading
Bispecific or trispecific antibodies that hold a natural killer cell against a tumour cell and switch it on, an alternative to T-cell engagers with potentially milder side effects.
Natural killer (NK) cell engagers bind an activating receptor on NK cells (CD16, NKG2D or NKp46) and a tumour antigen, often with an added interleukin-15 domain to sustain the cells. Programmes from Innate Pharma, Affimed and others are in early trials in lymphoma, leukaemia and solid tumours. Because NK cells release fewer inflammatory cytokines than T cells, the format promises less cytokine release syndrome, though clinical proof is limited.
Multispecific antibody scaffolds crosslink NK activating receptors with a tumour antigen, triggering degranulation and cytokine release against the bound target cell.
Query for this technology: (TITLE:"NK cell engagers" OR ABSTRACT:"NK cell engagers") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NK cell engagers, not a curated reading list.